Beyond improving traditional marketing metrics, a crucial new shared KPI for the CMO-CIO partnership is "Time to Value." This measures the efficiency of AI pilot selection, execution, and scaling, ensuring the collaboration delivers on AI's promise of speed without getting bogged down by process or governance hurdles.

DBS quantifies AI impact not by cost savings, but by the incremental revenue generated from AI-driven customer "nudges." Using rigorous A/B testing, they track the lift from these interactions, reframing AI's value proposition from an efficiency tool to a revenue growth engine, targeting over a billion dollars.

The true ROI of AI lies in reallocating the time and resources saved from automation towards accelerating growth and innovation. Instead of simply cutting staff, companies should use the efficiency gains to pursue new initiatives that increase demand for their products or services.

Focusing on AI for cost savings yields incremental gains. The transformative value comes from rethinking entire workflows to drive top-line growth. This is achieved by either delivering a service much faster or by expanding a high-touch service to a vastly larger audience ("do more").

AI requires significant upfront investment with uncertain returns, creating an "investment paradox" for CFOs. Traditional ROI models are insufficient. A new financial framework is needed that measures not just cost savings but also revenue acceleration, risk mitigation, and the strategic option value of competitive positioning.

Instead of abstract productivity metrics, define your AI goal in terms of concrete headcount avoidance. Sensei's objective is to achieve the output of a 700-person company with half the staff by using AI to bridge the gap. This makes the ROI tangible and aligns AI investment with scalable, capital-efficient growth.

The massive $700B capital injection into AI demands a return. The next few years will shift focus from hype to demonstrable results. Companies that can't show a quick, real, and efficient ROI will face a reckoning, even if they have grand aspirations.

A traditional IT investment ROI model misses the true value of AI in pharma. A proper methodology must account for operational efficiencies (e.g., time saved in clinical trials, where each day costs millions) and intangible benefits like improved data quality, competitive advantage, and institutional learning.

Snowflake's former CRO offers a pragmatic view of AI, calling it a 'task automator.' He stresses that for enterprise adoption, AI tools can't just be 'cool.' They must deliver a clear return on investment by either generating revenue or creating significant cost savings, like the 418 hours per week saved by their support team.